MedTrace Logo

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00758706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-04-16

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.

Conditions

Interventions

DRUG

AZD1236

oral tablet, 75 mg, twice daily during 6 weeks

DRUG

Placebo

Dosing to match AZD1236

Sponsors & Collaborators

Principal Investigators

  • Ronald Dahl, MD, Professor · Arhus Kommune HospitalMedicinsk

  • Andrew Lockton, MD · AstraZeneca R&D Charnwood

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Denmark
  • Finland
  • Netherlands
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00758706 on ClinicalTrials.gov